Clinical trial NCT06099886: Repurposing Lithium for Parkinson's Disease
Official title: Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Parkinson's Disease
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
Collaborators: name: National Center for Advancing Translational Sciences (NCATS)
First posted: 2023-10-25
Enrollment: 17
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

Detailed description: In observational studies, small daily doses of lithium have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventing neuronal death and behavioral symptoms in several PD animal models. Recently, our group has shown 24-weeks of low-dose lithium aspartate therapy 45mg/day in PD to engage blood-based and the MRI disease progression biomarker, free water, to a greater extent than 15mg/day or 150mg/day of lithium carbonate. However, these blood-based and MRI biomarker findings stem from only four and two PD patients, respectively, who received lithium aspartate 45mg/day. In addition, two other PD patients receiving this dosage withdrew from the study due to side effects of sedation and dizziness. Subsequently, one of these patients who withdrew resumed lithium aspartate at 30mg/day and reported no side effects. Although these findings suggest that this dosage of lithium aspartate has positive effects on PD biomarkers, data from a larger number of PD patients will be required to justify conducting a larger, randomized controlled trial (RCT). The proposed study will enroll 15 additional PD patients over five months who will receive lithium aspartate 30-45mg/day for 24 weeks ensuring that the study will be completed within 12 months. The dosage will be slowly titrated in each patient up to the maximum tolerated dosage in this range. Blood-based biomarkers and MRIs will be assessed at baseline and 24 weeks. It is anticipated that a similar magnitude of biomarker engagement will be observed among these additional 15 patients as was seen in the handful from the pilot study. Such findings would provide strong preliminary evidence to support conducting a larger RCT including both clinical and biomarker outcomes. Positive results from such a RCT would support lithium aspartate as a disease-modifying therapy for PD.

Eligibility criteria: Inclusion Criteria:

Have PD for \<4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD.

Have no use of tobacco or THC products for \>1 year. Have stable PD medications for \>30 days without current need for adjustments in the investigator's opinion.

Have stable psychiatric and diuretic medications for \>60 days with no anticipated need for changes for at least 24 weeks.

Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.

Exclusion Criteria:

Have PD for \>4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD.

Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion.

Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks.

Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.

Primary outcomes:
measure: MRI-derived free water (FW) levels
timeFrame: Change from baseline (BL) to 24 weeks.
measure: Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression.
timeFrame: Change from BL to 24 weeks.
Secondary outcomes:
measure: Serum neurofilament light (NfL)
timeFrame: Change from BL to 24 weeks.
measure: Serum glial fibrillary acidic protein (GFAP)
timeFrame: Change from BL to 24 weeks.
measure: PBMC superoxide dismutase type-1 (SOD-1) mRNA expression
timeFrame: Change from BL to 24 weeks.
measure: PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio
timeFrame: Change from BL to 24 weeks.
measure: PBMC pThr308 and pS473/total protein kinase B (Akt) ratios
timeFrame: Change from BL to 24 weeks.
measure: Serum interleukin-6
timeFrame: Change from BL to 24 weeks.
measure: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination)
timeFrame: Change from BL to 24 weeks.
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: Change from BL to 24 weeks.
measure: Parkinson's Anxiety Scale
timeFrame: Change from BL to 24 weeks.
measure: Geriatric Depression Scale-15
timeFrame: Change from BL to 24 weeks.
measure: Fatigue Severity Scale
timeFrame: Change from BL to 24 weeks.
measure: Insomnia Severity Index
timeFrame: Change from BL to 24 weeks.
measure: Parkinson's Disease Questionnaire-8
timeFrame: Change from BL to 24 weeks.
measure: Levodopa equilavent dose
timeFrame: Change from BL to 24 weeks.
Other outcomes:
measure: Adverse events
timeFrame: Through study completion, an average of 24 weeks.
Locations:
city: Williamsville
country: United States
facility: University at Buffalo
state: New York
Study officials:
References:
citation: Guttuso T Jr, Shepherd R, Frick L, Feltri ML, Frerichs V, Ramanathan M, Zivadinov R, Bergsland N. Lithium's effects on therapeutic targets and MRI biomarkers in Parkinson's disease: A pilot clinical trial. IBRO Neurosci Rep. 2023 May 7;14:429-434. doi: 10.1016/j.ibneur.2023.05.001. eCollection 2023 Jun.